Co-Diagnostics Forms New Artificial Intelligence Business Unit To Integrate Its Current, Planned AI Applications Into Co-Dx Primer Ai

Co-Diagnostics, Inc.

Co-Diagnostics, Inc.

CODX

0.00

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the formation of a newly organized, artificial intelligence ("AI") business unit, led by Chief Technology & AI Officer Christopher Thurston, to integrate the Company's existing and planned AI applications into the Co-Dx™ Primer Ai™ platform.

Co-Dx anticipates that allocating resources to the newly formed AI business unit will enable the Company to develop proprietary AI-powered diagnostics more efficiently and reduce time-to-market for new tests. The Company also believes that future AI tools will be able to leverage the analytics yielded from widespread deployment and commercialization of the Co-Dx PCR Pro* to improve situational awareness during a health crisis, and potentially predict outbreaks and pandemics before they occur.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.